Harmen Beurmanjer

167 Supplements Population description and results Demographics: 89% male; M=27.9, range 21-37 years; well-educated population (no further information). Other: 84% were gay men. Five patients were HIV-positive. GHB use: All patients used GBL around the clock daily (12-40ml). Most started GBL-use when attending nightclubs. Function of use: to achieve a state of sociable confidence, to facilitate sexual activity, and to sleep. Seven patients lost jobs due to GBL dependence and several others reported having concerns at work. Other substance use: Three patients had a prior history of substance dependence and all three dropped out. Frequent use of party drugs (ketamine, ecstasy, and methamphetamine) was common. Demographics: 73% male; M=26.8, SD=9.1 years; education: none (2.7%), lower secondary/ vocational (77.4%), higher secondary/ pre-university (13.4%), university and post-graduate (6.7%); living single (57.3%), with partner (30.7%), with parents (10.7%), with friends (1.3%); no work (48%), fulltime work (21.3%), part-time (22.7%), studying (8.0%). GHB use: First time use: past year (74.7%), > 1 year ago (14.7%), > 3 years ago (10.7%). DUDIT-score M=26.9, SD=7.3, 77% had DUDIT-score >25, indicating dependence. Motives for use: cheap (10,8%), sedation (26,3%), euphoria (54,0%), unsatisfied other drugs (18,7%), no hangovers (16,0%), better sex (18,0%), friends use it (39,7%), no motives (17,0%). Motives for seeking treatment: Sleep problems (30.7%), social problems (22.7%), psychological problems (20.0%), physical problems (18.6%), passing out (GHB coma) (8.0%). Other substance use: Last month use of alcohol (52%), cannabis (45.3%), ecstasy (24.0%), amphetamine (30.7%), cocaine (25.3). Last month co-use GHB and alcohol (44.0%), cannabis (36.0%), ecstasy (14.6%), amphetamine (25.3%), cocaine (22.7%). Demographics: 50% male; M=33.1, range 20-48 years; 42 % employed; household status: private rental (50%), no fixed address (25%), other (25%); single (58%), partnered (42%); legal issues: current (58%), never (25%), previous (17%). Other: heterosexual (42%), homosexual (25%), unknown (33%); HIV co-infection: yes (25%), no (33%), unknown (50%); comorbid mental health (92%), intravenous drug use: current (33%), previous (17%), never (50%); previous withdrawal management (42%); history of overdose (50%); referral pathway: self (42%), hospital (25%), other (33%). GHB use: Duration of use (months): M=60, median:27, range 3-216; amount used in 24h (ml): M=16, median=10, range 1.5-40; frequency of use: daily (75%), ≥ 2 times/week (25%). Other substance use (concomitant): stimulants (100%), tobacco (100%), cannabis (33%), alcohol (25%), benzodiazepine (25%), heroin (8%). Other: GHB use of greater than 90 ml in the previous 7 days was significantly associated with not completing treatment despite being administered diazepam and/or neuroleptic. Demographics: 85% male; M=27.5, SD=4.3 years. Other: Prior documented psychiatric disorder other than substance use in 30% (6/20). GHB use: median 27 (18 – 37) ml per day. Other substance use: co-ingestion with other substances in 71% (22/31): crystal meth (32.2%), cocaine (22.5%), alcohol (19.4%), MDMA (9.7%), Mephedrone (6.5), ketamine (3.2%), and cannabis (3.2%).